Michael Justus, PA
Surgical · Searcy, ARNPI 1538330220
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 464 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 464 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$1K
- Novartis$907
- Pfizer$716
- SK Life Science, Inc.$659
- Amgen$596
- plus $3K from 23 others
What the payments were for
- Food & beverage$8,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $1,168 |
| UCB, Inc. | 53 | $1,007 |
| Novartis | 48 | $907 |
| Pfizer | 63 | $716 |
| SK Life Science, Inc. | 31 | $659 |
| Amgen | 28 | $596 |
| Biogen | 34 | $583 |
| AstraZeneca | 21 | $391 |
| Amneal Pharmaceuticals LLC | 18 | $314 |
| Lundbeck LLC | 15 | $263 |
| Eisai Inc. | 9 | $175 |
| Neurelis, Inc. | 8 | $165 |
| Kyowa Kirin, Inc. | 7 | $161 |
| Lilly USA, LLC | 11 | $157 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $147 |
| Bristol Myers Squibb | 7 | $126 |
| Tanabe Pharma America, Inc. | 7 | $111 |
| Mallinckrodt Hospital Products Inc. | 4 | $101 |
| Neurocrine Biosciences, Inc. | 4 | $74 |
| Genentech USA, Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Corium, LLC | 5 | $60 |
| Medtronic | 2 | $54 |
| Sanofi | 2 | $51 |
| TG Therapeutics, Inc. | 2 | $49 |
| Argenx US, Inc. | 2 | $49 |
| Livanova USA, Inc. | 1 | $33 |
| Springworks Therapeutics, Inc. | 1 | $28 |
| CSL Behring | 1 | $22 |
How this compares
$8,294 in reported general payments places this provider in the 95th percentile of 30 surgical providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 64 | $597,440 |
| Aimovig AutoinjectorErenumab-Aooe | 148 | $150,065 |
| Nurtec OdtRimegepant Sulfate | 83 | $130,628 |
| UbrelvyUbrogepant | 50 | $67,079 |
| QuliptaAtogepant | 53 | $59,950 |
| BriviactBrivaracetam | 31 | $43,839 |
| Emgality PenGalcanezumab-Gnlm | 47 | $41,947 |
| NayzilamMidazolam | 14 | $17,183 |
| Pregabalin | 275 | $8,028 |
| Primidone | 272 | $4,787 |
| Levetiracetam | 132 | $3,955 |
| Carbamazepine ErCarbamazepine | 27 | $3,563 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 172 | $3,095 |
| Gabapentin | 226 | $2,737 |
| Memantine Hcl | 121 | $2,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $716 | $130,62883 claims |
| AbbVieUbrelvy, Qulipta | $1,168 | $127,029103 claims |
| UCB, Inc.Briviact, Nayzilam | $1,007 | $61,02245 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $314 | $2,90039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 surgical providers in Arkansas.
Other surgical in Searcy
- Lonny RameySearcy$18
- Anthony LongPine Bluff$4K
- Kierstin DaughertyNorth Little Rock$3K
- Clayton KiihnlBatesville$2K
- Matthew MillerLittle Rock$2K
- Courteney GoochLittle Rock$974
- Tara RogersConway$965
- Devon HughesLittle Rock$904
- William EllisLittle Rock$894
- David StreetBenton$879
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.